{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T09:42:21Z","timestamp":1784972541852,"version":"3.55.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.ygyno.2013.04.049","type":"journal-article","created":{"date-parts":[[2013,4,25]],"date-time":"2013-04-25T22:35:14Z","timestamp":1366929314000},"page":"19-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy"],"prefix":"10.1016","volume":"130","author":[{"given":"Robert M.","family":"Wenham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Lapolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin M.","family":"Apte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnathan M.","family":"Lancaster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia L.","family":"Judson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Gonzalez-Bosquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Herschberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Havrilesky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeles Alvarez","family":"Secord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2013.04.049_bb0005","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.ygyno.2004.12.001","article-title":"Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer","volume":"96","author":"Monk","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0010","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0015","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0020","first-page":"28","article-title":"OCEANS: a randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC)","author":"Aghajanian","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0025","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Burger","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0030","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0035","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","article-title":"Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia","volume":"26","author":"Garcia","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0040","first-page":"30","article-title":"AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC)","author":"Pujade-Lauraine","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0045","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0090-8258(02)00091-4","article-title":"A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study","volume":"88","author":"Rose","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0050","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1023\/A:1008337103708","article-title":"A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: a Japanese cooperative study","volume":"11","author":"Katsumata","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0055","first-page":"1997","article-title":"Phase I clinical trial of RP 56976 (docetaxel) a new anticancer drug","volume":"21","author":"Taguchi","year":"1994","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0060","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1136\/ijgc-00009577-200309000-00018","article-title":"Effective weekly docetaxel for recurrent ovarian cancer: a case report","volume":"13","author":"Komiyama","year":"2003","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0065","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ygyno.2006.12.018","article-title":"Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial","volume":"105","author":"Kushner","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0070","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000224658","article-title":"A feasibility study of weekly docetaxel with capecitabine in ovarian cancer: a promising combination of two active drugs with a potential for synergism","volume":"55","author":"Safra","year":"2009","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0075","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ygyno.2009.02.018","article-title":"A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers","volume":"113","author":"Gupta","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0080","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ygyno.2006.10.006","article-title":"Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel\u2014ANZGOG 02-01","volume":"104","author":"Tinker","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0085","first-page":"299","article-title":"A pilot study of weekly docetaxel therapy for recurrent ovarian cancer, tubal cancer, and primary peritoneal cancer","volume":"26","author":"Komiyama","year":"2005","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0090","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1586\/14737140.5.2.203","article-title":"Docetaxel in the management of ovarian cancer","volume":"5","author":"Blagden","year":"2005","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0095","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ygyno.2004.08.028","article-title":"A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer","volume":"95","author":"Berkenblit","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0100","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s10147-003-0351-7","article-title":"Weekly docetaxel for patients with platinum\/paclitaxel\/irinotecan-resistant relapsed ovarian cancer: a phase I study","volume":"8","author":"Terauchi","year":"2003","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0105","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0090-8258(03)00322-6","article-title":"A feasibility study on biweekly administration of docetaxel for patients with recurrent ovarian cancer","volume":"90","author":"Oishi","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0110","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1200\/JCO.1994.12.7.1458","article-title":"Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis","volume":"12","author":"Tomiak","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0115","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ygyno.2006.01.030","article-title":"Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer","volume":"102","author":"Cohn","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0120","doi-asserted-by":"crossref","first-page":"9033","DOI":"10.1158\/0008-5472.CAN-08-1723","article-title":"Efficacy of weekly docetaxel and bevacizumab in mesenchymal chondrosarcoma: a new theranostic method combining xenografted biopsies with a mathematical model","volume":"68","author":"Gorelik","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0125","first-page":"1191","article-title":"Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (taxotere): association with impaired repositioning of the microtubule organizing center","volume":"1","author":"Hotchkiss","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0130","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1158\/1078-0432.CCR-05-2603","article-title":"Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients","volume":"12","author":"Ramaswamy","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0135","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/jnci\/92.18.1534","article-title":"Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic cancer intergroup","volume":"92","author":"Vergote","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0140","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.ygyno.2011.04.005","article-title":"Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study","volume":"122","author":"Herzog","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0145","first-page":"1","article-title":"The natural duration of cancer. Reports on public health and medical subjects","volume":"33","author":"Greenwood","year":"1926","journal-title":"London: Her Majesty's Stationery Office"},{"issue":"282","key":"10.1016\/j.ygyno.2013.04.049_bb0150","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0155","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3109\/07357907.2012.657812","article-title":"Phase II study of gemcitabine and docetaxel in recurrent platinum resistant ovarian cancer","volume":"30","author":"Garcia","year":"2012","journal-title":"Cancer Invest"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0160","first-page":"3559","article-title":"Docetaxel in combination with irinotecan (CPT-11) in platinum-resistant paclitaxel-pretreated ovarian cancer","volume":"25","author":"Polyzos","year":"2005","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0165","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s10147-011-0353-9","article-title":"Docetaxel\/irinotecan combination chemotherapy in platinum\/taxane-refractory and -resistant ovarian cancer: JGOG\/WJGOG Intergroup Study","volume":"18","author":"Ushijima","year":"2013","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0170","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1093\/annonc\/mdg292","article-title":"Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer","volume":"14","author":"Aravantinos","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0175","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/cncr.23605","article-title":"Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial","volume":"113","author":"Matei","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0180","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S1470-2045(11)70244-3","article-title":"Phase 1\u20132 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer","volume":"12","author":"Coleman","year":"2011","journal-title":"Lancet Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2013.04.049_bb0185","first-page":"S106","article-title":"Phase II trial of neoadjuvant docetaxel with or without bevacizumab in patients with locally advanced breast cancer","volume":"88","author":"Overmoyer","year":"2004","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0190","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1200\/JCO.2008.21.6457","article-title":"Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"28","author":"Miles","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0195","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/cncr.23374","article-title":"Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy","volume":"112","author":"Azad","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0200","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1002\/cncr.23893","article-title":"Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy","volume":"113","author":"Markman","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0205","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1016\/j.ejca.2010.07.021","article-title":"Bevacizumab\/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment","volume":"46","author":"Ortholan","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0210","first-page":"3369","article-title":"The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors","volume":"61","author":"Sweeney","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0215","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1089\/152581602753448577","article-title":"Docetaxel versus paclitaxel for antiangiogenesis","volume":"11","author":"Vacca","year":"2002","journal-title":"J Hematother Stem Cell Res"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0220","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ijc.10907","article-title":"Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere)","volume":"104","author":"Grant","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0225","first-page":"308","article-title":"Bevacizumab, paclitaxel and carboplatin for advanced ovarian cancer: low risk of gastrointestinal and cardiovascular toxicity","volume":"31","author":"Abaid","year":"2010","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0230","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ygyno.2009.11.017","article-title":"Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma","volume":"116","author":"Diaz","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0235","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ygyno.2010.01.011","article-title":"Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?","volume":"118","author":"Richardson","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0240","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ygyno.2010.11.009","article-title":"Clinical predictors of bevacizumab-associated gastrointestinal perforation","volume":"120","author":"Tanyi","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0245","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ygyno.2009.05.031","article-title":"The risk of gastrointestinal perforation and\/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study","volume":"114","author":"Sfakianos","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.04.049_bb0250","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1684\/bdc.2011.1436","article-title":"Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study","volume":"98","author":"Asmane","year":"2011","journal-title":"Bull Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813003053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813003053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:34:49Z","timestamp":1758771289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825813003053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S0090825813003053"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.04.049","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718003868.793478003","asserted-by":"object"}]},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.04.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}